4//SEC Filing
CR Group L.P. 4
Accession 0001415889-24-013055
CIK 0001492674other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 6:19 PM ET
Size
19.4 KB
Accession
0001415889-24-013055
Insider Transaction Report
Form 4
Capital Royalty L.P.
10% Owner
Transactions
- Conversion
Common Stock
2024-05-09+1,716,048→ 4,595,977 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series A Preferred Stock
2024-05-09−17,160.48→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (1,716,048 underlying) - Conversion
Common Stock
2024-05-09+108,752→ 4,704,729 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series B Preferred Stock
2024-05-09−10,875.25→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (108,752 underlying)
Transactions
- Conversion
Common Stock
2024-05-09+1,716,048→ 4,595,977 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Common Stock
2024-05-09+108,752→ 4,704,729 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series A Preferred Stock
2024-05-09−17,160.48→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (1,716,048 underlying) - Conversion
Series B Preferred Stock
2024-05-09−10,875.25→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (108,752 underlying)
Transactions
- Conversion
Series B Preferred Stock
2024-05-09−10,875.25→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (108,752 underlying) - Conversion
Common Stock
2024-05-09+1,716,048→ 4,595,977 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series A Preferred Stock
2024-05-09−17,160.48→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (1,716,048 underlying) - Conversion
Common Stock
2024-05-09+108,752→ 4,704,729 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)
Transactions
- Conversion
Common Stock
2024-05-09+108,752→ 4,704,729 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series B Preferred Stock
2024-05-09−10,875.25→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (108,752 underlying) - Conversion
Common Stock
2024-05-09+1,716,048→ 4,595,977 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series A Preferred Stock
2024-05-09−17,160.48→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (1,716,048 underlying)
CRG Partners III L.P.
10% Owner
Transactions
- Conversion
Common Stock
2024-05-09+108,752→ 4,704,729 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series A Preferred Stock
2024-05-09−17,160.48→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (1,716,048 underlying) - Conversion
Series B Preferred Stock
2024-05-09−10,875.25→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (108,752 underlying) - Conversion
Common Stock
2024-05-09+1,716,048→ 4,595,977 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)
Transactions
- Conversion
Common Stock
2024-05-09+1,716,048→ 4,595,977 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Common Stock
2024-05-09+108,752→ 4,704,729 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series B Preferred Stock
2024-05-09−10,875.25→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (108,752 underlying) - Conversion
Series A Preferred Stock
2024-05-09−17,160.48→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (1,716,048 underlying)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock converted into 100 shares of Common Stock for no additional consideration and has no expiration date.
- [F2]CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
- [F3]Each share of Series B Preferred Stock converted into 10 shares of Common Stock for no additional consideration and has no expiration date.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001702352
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 6:19 PM ET
- Size
- 19.4 KB